SciFi Advisor
Event-driven, biotech, healthcare, small-cap

Clearing Up Misconceptions About NeoStem's AMR-001

A recent article criticizing NeoStem's (NBS) lead program AMR-001 described skepticism that the Phase II trial will yield positive data later this year. Unfortunately, the points that were brought up mischaracterize the program, with a misunderstanding of some important basics of the trial. In this article, I will walk through the arguments surrounding AMR-001 and provide an alternative argument for why the Phase II trial is designed appropriately, is based on science, and should be more carefully considered.

Trial Enrollment

AMR-001 is an autologous stem cell therapy derived from a patient's own bone-marrow cells, which is delivered through the intracoronary artery after a heart attack. The goal of treatment is restoration of blood flow, reducing cardiac tissue damage, and improving...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details